Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia.
Standard
Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia. / Suarez, D; Haro, J M; Novick, D; Perrin, E; Ochoa, S; Naber, Dieter.
In: PHARMACOPSYCHIATRY, Vol. 42, No. 4, 4, 2009, p. 135-140.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia.
AU - Suarez, D
AU - Haro, J M
AU - Novick, D
AU - Perrin, E
AU - Ochoa, S
AU - Naber, Dieter
PY - 2009
Y1 - 2009
N2 - INTRODUCTION: Antipsychotic treatment dose adjustments may influence treatment outcomes in patients with schizophrenia. METHODS: We analysed data from 4,247 outpatients with schizophrenia who started olanzapine monotherapy in the 3-year, prospective, observational SOHO study to determine factors associated with olanzapine dose adjustments and how these impact on treatment effectiveness and tolerability. RESULTS: Regression analyses showed an association between changes in the Clinical Global Impression (CGI) and olanzapine dose changes: patients with a lack of effectiveness were more likely to have their dose increased, whereas patients with good treatment response were more likely to have a dose decrease. Improvement in tardive dyskinesia was associated with dose increase or no change (p=0.034) and worsening of sexual problems was associated with dose decrease (p=0.001). Conversely, an increase in olanzapine dose was associated with subsequent clinical improvement (CGI), but dose adjustment had no significant effects on tolerability outcomes. DISCUSSION: These results indicate that psychiatrists tend to modify olanzapine dose according to treatment response. Dose increases seem to be associated with a better response to treatment and not with a worsening of side-effects.
AB - INTRODUCTION: Antipsychotic treatment dose adjustments may influence treatment outcomes in patients with schizophrenia. METHODS: We analysed data from 4,247 outpatients with schizophrenia who started olanzapine monotherapy in the 3-year, prospective, observational SOHO study to determine factors associated with olanzapine dose adjustments and how these impact on treatment effectiveness and tolerability. RESULTS: Regression analyses showed an association between changes in the Clinical Global Impression (CGI) and olanzapine dose changes: patients with a lack of effectiveness were more likely to have their dose increased, whereas patients with good treatment response were more likely to have a dose decrease. Improvement in tardive dyskinesia was associated with dose increase or no change (p=0.034) and worsening of sexual problems was associated with dose decrease (p=0.001). Conversely, an increase in olanzapine dose was associated with subsequent clinical improvement (CGI), but dose adjustment had no significant effects on tolerability outcomes. DISCUSSION: These results indicate that psychiatrists tend to modify olanzapine dose according to treatment response. Dose increases seem to be associated with a better response to treatment and not with a worsening of side-effects.
M3 - SCORING: Zeitschriftenaufsatz
VL - 42
SP - 135
EP - 140
JO - PHARMACOPSYCHIATRY
JF - PHARMACOPSYCHIATRY
SN - 0176-3679
IS - 4
M1 - 4
ER -
